Peer-reviewed Publication Shows that Lateral Pharma's SCP Drugs for Neuropathic Pain Act Via the Novel Target LanCL1
MELBOURNE, Australia, June 12, 2026 /PRNewswire/ -- Lateral Pharma announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain,...
MELBOURNE, Australia, June 12, 2026 /PRNewswire/ -- Lateral Pharma announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.